Printer Friendly

BRISTOL-MYERS SQUIBB ANNOUNCES OFFERING

 NEW YORK, May 27 /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE: BMY) announced today the offering of $350 million principal amount of 7.15 percent debentures due 2023. The debentures are being offered to the public at 98.5 percent of their principal amount. Salomon Brothers Inc is the sole underwriter of the offering. Proceeds from the sale of these securities will be used for general corporate purposes, which may include, without limitation, working capital, capital expenditures, stock purchase programs, repayment or refinancing of borrowings, and acquisitions. The prospectus relating to these securities may be obtained from Salomon Brothers Inc, 7 World Trade Center, New York, New York 10048, by calling the Prospectus Department at, 718-783-1400.
 -0- 5/27/93
 /CONTACT: Anthony Carter of Bristol-Myers Squibb Company, 212-546-4339/
 (BMY)


CO: Bristol-Myers Squibb Company ST: New York IN: MTC SU: OFR

LD -- NY091 -- 3129 05/27/93 16:53 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 27, 1993
Words:147
Previous Article:LECHTERS INC. REPORTS RESULTS
Next Article:SOUTHDOWN, INC. BOARD SETS DIVIDEND PAYOUT
Topics:


Related Articles
BRISTOL-MYERS SQUIBB ANNOUNCES AGREEMENT WITH SCHERING AG
BRISTOL-MYERS SQUIBB ANNOUNCES COURT RULING
BRISTOL-MYERS SQUIBB ANNOUNCES SALE
BRISTOL-MYERS SQUIBB SUPPORTS NATIONAL CANCER ORGANIZATION AND TOP FEMALE VOCALISTS TO ENCOURAGE BREAST HEALTH AWARENESS
BRISTOL-MYERS SQUIBB TO ACQUIRE CALGON VESTAL LABORATORIES FROM MERCK
BRISTOL-MYERS SQUIBB INVESTS IN SOMATIX; COMPANIES TO EVALUATE POSSIBLE AREAS FOR COLLABORATION IN GENE THERAPY
BRISTOL-MYERS SQUIBB FILES CLAIMS AGAINST CANADIAN COMPANY FOR MISREPRESENTATION OF ANTICANCER PRODUCT
BRISTOL-MYERS SQUIBB AND IXSYS SIGN $40 MILLION RESEARCH PACT; TUMOR ANTIGEN COLLABORATION FOLLOWS SUCCESS OF EARLIER PARTNERSHIP
BRISTOL-MYERS SQUIBB TO ACQUIRE HUNGARIAN HEALTH CARE COMPANY
Bristol-Myers Squibb to Seek Buyer for Its Infection Control and Contamination Control Businesses

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters